Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder
2001
Genetic Changes Linked to Bladder Cancer Recurrence
Sample size: 109
publication
Evidence: moderate
Author Information
Author(s): Edwards J, Duncan P, Going J J, Grigor K M, Watters A D, Bartlett J M S
Primary Institution: University Department of Surgery, Glasgow Royal Infirmary
Hypothesis
Can genetic alterations on chromosomes 4, 8, 11, and 17 predict recurrence in transitional cell carcinoma (TCC) of the bladder?
Conclusion
Loss of heterozygosity on chromosomes 11 and 17 is associated with a higher risk of recurrence in bladder cancer.
Supporting Evidence
- Approximately 2/3 of patients diagnosed with superficial TCC will recur within 2 years.
- Loss of chromosome 9 and LOH at 9q34 identify a subset of patients at high risk of recurrence.
- LOH of D11S490 or D17S928 was significantly more frequent in patients who experienced recurrence.
Takeaway
This study found that certain genetic changes in bladder cancer can help predict if the cancer will come back.
Methodology
DNA was extracted from microdissected archival normal/tumour tissue and analyzed for loss of heterozygosity at 26 loci using fluorescent PCR and genotyping.
Statistical Information
P-Value
0.004 and 0.019
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website